ArticleEmerging microbes & infections2026
A novel assay for quantifying Gn-LRP1-mediated neutralizing antibodies against severe fever with thrombocytopenia syndrome virus.
Article in Emerging microbes & infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate and efficient determination of neutralizing antibody (nAb) is critical for assessing individual immune status of severe fever with thrombocytopenia syndrome (SFTS) and identifying key ecological reservoirs of the SFTS virus (SFTSV). However, conventional virus neutralization tests (cVNT) require live virus and are limited by their inability to support rapid, high-throughput screening. Here, we report a novel SFTSV virus neutralization test targeting the interaction between the SFTSV Gn protein and its receptor (LRP1). The test, which has been validated with SFTS patient plasma, achieves a sensitivity of 96.79% and a specificity of 100%. It also shows good correlation with cVNT, with an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.